Pain News and Research

Latest Pain News and Research

University of Surrey lecturer on Co-sleeping

The event will be a series of overlapping presentations based on video clips of older people talking about their experience of poor sleep, and the impact this has on their lives. The presenters are all involved in the SomnIA (Sleep in Ageing) project based at the University of Surrey. As well as the video-based presentations and discussions, members of the audience will be invited to share some of their own experiences of poor sleep, and write down questions which they would like the panel of presenters to address during the last part of the event.

11 Sep 2009

Dyax' Phase 3 hereditary angioedema clinical program affirms reliability of its novel PROs

Dyax Corp. (NASDAQ:DYAX) today announced a study published evaluating the Company’s novel Patient Reported Outcome Measures (PROs) used to assess hereditary angioedema (HAE) attacks affirmed the PROs as valuable instruments in capturing HAE symptom severity and impact of treatment.

11 Sep 2009

USPTO recognizes RZN Nutraceuticals' HerbaZorb as a patentable delivery system

RZN Nutraceuticals, Inc.,(www.rznnutra.com) a leading developer of proven effective herbal products which have been clinically tested on sufferers of severe arthritis and migraines has announced receipt of a Notice of Allowance from the U.S. Patent and Trademark Office for the firm's absorption and delivery system process methodology patent application, a technology RZN has named HerbaZorb(TM).

11 Sep 2009

PPJ Enterprise focuses on business development of the medical billing firm PBS

PPJ Enterprise (PPJ) (PINKSHEETS: PPJE), a leader in proprietary automated healthcare multi-specialty provider reimbursement cycle technology and EHR development/information management digital system software for health care providers. PPJ Enterprises has focused all of its resources currently on the strategic business development of the medical billing firm PBS.

11 Sep 2009

Cymbalta maintains reduction in pain for patients with chronic low back pain

New data show patients with chronic low back pain on Cymbalta(R) (duloxetine HCl) maintained reductions in pain for 41 weeks. In patients who initially responded to duloxetine, this maintenance of pain reduction was accompanied by further reduction in pain that was statistically significant as measured by the Brief Pain Inventory (BPI) average pain rating.

11 Sep 2009

Phase 3 trial results of LEVADEX orally inhaled migraine therapy to be presented

MAP Pharmaceuticals, Inc. announced today that it will present analysis of data from the efficacy portion of the first Phase 3 trial of its novel LEVADEX orally inhaled migraine therapy, currently in development, at the 14th Congress of the International Headache Society.

11 Sep 2009

President Obama's support for mapractice reform finds favour with 87% of surveyed physicians

Physicians across the US are speaking out on Sermo (http://www.sermo.com), the largest online physician community, discussing the President’s newly announced support for malpractice reform. According to a new survey conducted on Sermo of 3,102 US physicians, 87% stated they are more inclined to support a healthcare reform bill that includes malpractice reform.

11 Sep 2009

Merck update on the status of telcagepant clinical development programs

Merck & Co., Inc. today updated the status of the clinical development programs for telcagepant (MK-0974) and MK-3207, the Company's investigational oral calcitonin gene-related peptide (CGRP) receptor antagonists for the intermittent treatment of acute migraine.

11 Sep 2009

New data reveals the efficacy of Instanyl in management of breakthrough cancer pain

New data presented today further demonstrate the efficacy of Instanyl in management of breakthrough cancer pain. The data which were presented at the 6th congress of the European Federation of Chapters of the International Association for the Study of Pain (EFIC) are from a multinational, crossover trial comparing Instanyl with oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in patients with cancer.

11 Sep 2009

Campaign to educate customers on chronic pain management

VitalWear, Inc. (www.vitalwear.com), a leader in thermal compression medical devices announced that it is launching a Direct Mail and Web campaign in an effort to educate customers on a recent report from the Center for Disease Control (CDC), stating that among all diabetics, 52% suffer from arthritis.

11 Sep 2009

Efficacy of Instanyl in management of breakthrough cancer pain demonstrated

11 Sep 2009

Researchers discover the role of endothelin in vaso-occlusive pain

Agonizing physical pain, known as vaso-occlusive pain, can afflict children who have sickle cell disease (SCD). In some cases infants as young as two months of age suffer vaso-occlusive pain so severe that opiate medications and hospitalizations are their only relief. Researchers believe vaso-occlusion is caused by a blockage of the blood vessels that occurs when sickle shaped red cells attempt to pass through the round blood vessels.

11 Sep 2009

Scientist awarded grant to study the role of VENs in quick decision making

A scientist at Barrow Neurological Institute at St. Joseph's Hospital and Medical Center has been awarded a $400,000 grant from the James S. McDonnell Foundation to help study a rare cell type that is believed to play a role in quick decision making and intuition. Abnormalities in this cell type have been seen in people suffering from autism and dementia.

10 Sep 2009

Improving childhood immunization campaigns could reduce sickle-cell deaths in Africa, Study finds

By offering all children in Africa vaccines that protect against bacterial infections, researchers say the number of deaths among children living with sickle-cell anemia could be reduced, Reuters reports. An estimated 200,000 children in Africa annually are born with sickle-cell anemia, a genetic disease "in which red blood cells deform into a sickle shape and cluster, blocking blood flow and causing pain, vulnerability to infections and organ damage."

10 Sep 2009

Phase III trial demonstrates rapid efficacy of Zelrix in treating acute migraine

NuPathe Inc., a specialty pharmaceutical company developing innovative products for the treatment of neurological and psychiatric diseases, today announced data from the pivotal Phase III trial of Zelrix™, a novel transdermal patch in clinical development for the treatment of acute migraine. Zelrix combines NuPathe’s proprietary SmartRelief™ iontophoretic transdermal technology with sumatriptan, the most prescribed treatment for acute migraine in the United States.

10 Sep 2009

Health care reform should tackle food safety

Linda Rivera’s excruciating case of food poisoning (Severe Case Gives Context to Issue of Food Safety Washington Post 9/1/09) should shine some light on a crucial reality that is missing from most health care reform plans: you can’t fix America’s health care unless you provide Americans with a safe food supply.

10 Sep 2009

Lock-Tight Facet Fixation System used performing posterior spinal fixation procedures

Spine surgeon David Raskas, M.D. at the Frontenac Surgery and Spine care Center has been performing outpatient, minimally invasive, posterior spinal fixation procedures on patients using the Lock-Tight Facet Fixation System, a unique technology that enables surgeons to fixate the facet joint without needing to perform an open procedure that usually requires fastening and fixating with pedicle screws and rods.

10 Sep 2009

Efficacy of Ore Pharmaceuticals' lead drug candidate discussed

Ore Pharmaceuticals Inc., announced today the publication of an article in the online version of the journal Inflammation Research titled, “Effects of the ACE2 inhibitor GL1001 on acute dextran sodium sulfate-induced colitis in mice.”

10 Sep 2009

Heavy school bags can cause back and spine injuries

Function and comfort over fashion is the goal this year as the kids head back to school. Starting today, the British Columbia Chiropractic Association is again launching television information to educate parents and inform them about the potential health risks an overweight back pack can cause on the early development of their children's backs.

10 Sep 2009

GlaxoSmithKline's CERVARIX receives favorable recommendation from FDA Advisory Committee

GlaxoSmithKline (NYSE: GSK) announced today that the U.S. Food and Drug Administration's (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted that clinical data support both the efficacy and safety of CERVARIX((R)), the company's candidate cervical cancer vaccine (12-1 and 11-1, respectively).

10 Sep 2009

Pain News and Research

Latest Pain News and Research

University of Surrey lecturer on Co-sleeping

Dyax' Phase 3 hereditary angioedema clinical program affirms reliability of its novel PROs

USPTO recognizes RZN Nutraceuticals' HerbaZorb as a patentable delivery system

PPJ Enterprise focuses on business development of the medical billing firm PBS

Cymbalta maintains reduction in pain for patients with chronic low back pain

Phase 3 trial results of LEVADEX orally inhaled migraine therapy to be presented

President Obama's support for mapractice reform finds favour with 87% of surveyed physicians

Merck update on the status of telcagepant clinical development programs

New data reveals the efficacy of Instanyl in management of breakthrough cancer pain

Campaign to educate customers on chronic pain management

Efficacy of Instanyl in management of breakthrough cancer pain demonstrated

Researchers discover the role of endothelin in vaso-occlusive pain

Scientist awarded grant to study the role of VENs in quick decision making

Improving childhood immunization campaigns could reduce sickle-cell deaths in Africa, Study finds

Phase III trial demonstrates rapid efficacy of Zelrix in treating acute migraine

Health care reform should tackle food safety

Lock-Tight Facet Fixation System used performing posterior spinal fixation procedures

Efficacy of Ore Pharmaceuticals' lead drug candidate discussed

Heavy school bags can cause back and spine injuries

GlaxoSmithKline's CERVARIX receives favorable recommendation from FDA Advisory Committee

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Pain News and Research

Latest Pain News and Research

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Newsletters you may be interested in